Zymeworks Chief People Officer Speaks with Life Science Leader About Company Initiatives Designed to Meet Evolving Needs of Its People
Zymeworks To Present At 40th Annual J.P. Morgan Healthcare Conference
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
Zymeworks Announces Second Janssen Bispecific Antibody To Begin Clinical Development Utilizing Azymetric™ And EFECT™ Therapeutic Platforms
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Mediacorp Recognizes Zymeworks as One of Canada’s 2022 Top 100 Employers
Zymeworks Launches Global Phase 3 Zanidatamab Trial In First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
Zymeworks-GSK Collaboration Leads To Design and Validation of a Novel Engineered, FcγRIIb-Selective Fc Platform for Therapeutic Antibody Development
November is Stomach Cancer Awareness Month
Zymeworks Shares Perspective on the Promise of Multi-Specific Antibodies at Digital STAT News Event
Zymeworks Announces Webcast To Present HERIZON-GEA-01 Pivotal Trial Design And Zanidatamab Commercial Strategy In Gastrointestinal Cancers
Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate And Durability In First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) At The European Society For Medical Oncology (ESMO) Annual Congress
Cholangiocarcinoma Foundation (CCF) Launches Program to Support Newly Diagnosed Patients and Their Caregivers
Great Place to Work Canada Names Zymeworks Among 2021 Best Workplaces™ In Healthcare
Zymeworks Announces Abstract For Zanidatamab In First-Line HER2-Expressing Gastroesophageal Cancers (GEA) At The European Society For Medical Oncology (ESMO) Annual Congress
Zymeworks Recognized Among Canada’s 2021 Best Workplaces™ for Giving Back
Zymeworks Reports 2021 Second Quarter Financial Results
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
Zymeworks Team Carries the Journey of Hope Torch to Hope, Canada
Zymeworks Supports Dave’s 15,000 Mile Journey of Hope
Zymeworks to Present at Jefferies Virtual Healthcare Conference
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
FDA Clears Zanidatamab Phase 3 Pivotal Trial in First Line HER2-positive Gastroesophageal Adenocarcinoma
Zymeworks Reports 2021 First Quarter Financial Results
Zymeworks to Present at Bloom Burton Healthcare Conference
Zymeworks Introduces Fourth Therapeutic Platform, ProTECT™
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting
Congratulations to Zymeworks Scientist Anna von Rossum, Healthcare Business Women’s Association 2021 Rising Star!
Zymeworks is Proud of Two National Top Employer Recognitions Received in Canada, and Even Prouder of Our People Who Make Zymeworks Such a Great Place to Work!
.jpg?width=416&height=243&mode=crop)
.jpg?width=416&height=243&mode=crop)
.jpg?width=416&height=243&mode=crop)
